Monopar Therapeutics (MNPR): Piper Sandler sees potential for ALXN1840 in treating Wilson disease

Monopar Therapeutics Inc. (MNPR) is a biotechnology company focused on developing innovative treatments for patients with unmet medical needs. The emphasis is particularly on radiopharmaceuticals for cancer diagnosis and therapy, as well as a drug for the rare Wilson disease. With its promising projects in clinical development, the company is increasingly attracting the attention of investors. The pipeline is currently wide-ranging. MNPR-101-Zr is an example of a radiopharmaceutical that targets and visualizes cancerous diseases and is being tested...